AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35960115 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ultrasonic debridement and cortex phellodendri compound fluid (CPCF)
Number of subjects: 0
Study 35960115 — intervention group
Group type: COMPARATOR
Intervention: Kangfuxin liquid
Number of subjects: 0
Study 35960115 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ultrasonic debridement and CPCF
Number of subjects: 0
Study 33827990 — intervention group
Group type: EXPERIMENTAL
Intervention: AD-203 (rebamipide 150 mg) twice daily for 2 weeks
Number of subjects: 475
Study 33827990 — intervention group
Group type: COMPARATOR
Intervention: Mucosta (rebamipide 100 mg) thrice daily for 2 weeks
Number of subjects: 475
Study 33827990 — intervention group
Group type: EXPERIMENTAL
Intervention: AD-203 (rebamipide 150 mg)
Number of subjects: 475
Study 33827990 — intervention group
Group type: COMPARATOR
Intervention: Mucosta (rebamipide 100 mg)
Number of subjects: 475
Study 34609547 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmalyte‐148 (PL)
Number of subjects: 90
Study 34609547 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride 0.9% (SC)
Number of subjects: 90
Study 35395741 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified antenatal care (MAC) program with 4 in-person visits and 2 virtual meetings
Number of subjects: 8200
Study 35395741 — intervention group
Group type: COMPARATOR
Intervention: Standard antenatal care (SAC) program with 8 in-person visits
Number of subjects: 8200
Study 33059669 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-lasting insecticide-treated bed nets (LLINs) ownership
Number of subjects: 2261
Study 33059669 — intervention group
Group type: EXPERIMENTAL
Intervention: LLINs utilization
Number of subjects: 2261
Study 33059669 — intervention group
Group type: EXPERIMENTAL
Intervention: LLIN ownership
Number of subjects: 2261
Study 33059669 — intervention group
Group type: EXPERIMENTAL
Intervention: LLIN utilization conditional to presence of at least one net
Number of subjects: 2261
Study 36271898 — intervention group
Group type: EXPERIMENTAL
Intervention: $10 financial incentive
Number of subjects: 5200
Study 36271898 — intervention group
Group type: EXPERIMENTAL
Intervention: $20 financial incentive
Number of subjects: 5200
Study 36271898 — intervention group
Group type: EXPERIMENTAL
Intervention: $40 financial incentive
Number of subjects: 5200
Study 36271898 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed letters
Number of subjects: 5200
Study 36271898 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated calls
Number of subjects: 5200
Study 36271898 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no financial incentive)
Number of subjects: 5200
Study 36271898 — intervention group
Group type: EXPERIMENTAL
Intervention: Time since enrollment (3 months)
Number of subjects: 5200
Study 36271898 — intervention group
Group type: EXPERIMENTAL
Intervention: Time since enrollment (12 months)
Number of subjects: 5200
Study 32651644 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (1000 mg) + Codeine (30 mg)
Number of subjects: 39
Study 32651644 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen (1000 mg)
Number of subjects: 39
Study 32651644 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Acetaminophen and Acetaminophen + Codeine)
Number of subjects: 39
Study 32186286 — intervention group
Group type: COMPARATOR
Intervention: Regular Platform (RP) implants
Number of subjects: 18
Study 32186286 — intervention group
Group type: EXPERIMENTAL
Intervention: Platform Switching (PS) implants
Number of subjects: 18
Study 34853186 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle joint cooling
Number of subjects: 20
Study 34853186 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee joint cooling
Number of subjects: 20
Study 34853186 — intervention group
Group type: COMPARATOR
Intervention: Control (seated without cooling)
Number of subjects: 20
Study 32658610 — intervention group
Group type: EXPERIMENTAL
Intervention: udenafil treatment
Number of subjects: 2
Study 32658610 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 2
Study 34792094 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc-biofortified rice (BFR)
Number of subjects: 520
Study 34792094 — intervention group
Group type: COMPARATOR
Intervention: Control rice (CR)
Number of subjects: 520
Study 33179377 — intervention group
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin 2.5 mg/kg
Number of subjects: 196
Study 33179377 — intervention group
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin 3.4 mg/kg
Number of subjects: 196
Study 35886341 — intervention group
Group type: EXPERIMENTAL
Intervention: Iontophoresis with Perskindol gel from the positive pole ("+" iontophoresis)
Number of subjects: 100
Study 35886341 — intervention group
Group type: COMPARATOR
Intervention: Iontophoresis with Perskindol gel from the negative pole ("-" iontophoresis)
Number of subjects: 100
Study 35886341 — intervention group
Group type: COMPARATOR
Intervention: Anodic galvanic treatment
Number of subjects: 100
Study 33651976 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to CONSORT guidelines
Number of subjects: 80
Study 33651976 — intervention group
Group type: EXPERIMENTAL
Intervention: CONSORT items adherence
Number of subjects: 80
Study 33651976 — intervention group
Group type: EXPERIMENTAL
Intervention: Underreported CONSORT items
Number of subjects: 80
Study 33651976 — intervention group
Group type: EXPERIMENTAL
Intervention: Journals' recommendations
Number of subjects: 80
Study 32443285 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment and prolonged antimicrobial therapy (median duration of antibiotics was 12 weeks)
Number of subjects: 37
Study 32443285 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 37
Study 35490396 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdraw from ASMs
Number of subjects: 1004
Study 35490396 — intervention group
Group type: COMPARATOR
Intervention: Continue ASMs
Number of subjects: 1004
Study 35329209 — intervention group
Group type: EXPERIMENTAL
Intervention: Menthol mouth rinse (0.1%)
Number of subjects: 11
Study 35329209 — intervention group
Group type: COMPARATOR
Intervention: Cold water mouth rinse (WAT)
Number of subjects: 11
Study 35329209 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouth rinse (PLA)
Number of subjects: 11
Study 36003294 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (RIC) - four cycles of 5 min blood pressure cuff inflation at 200 mmHg followed by 5 min reperfusion on the unaffected thigh.
Number of subjects: 400
Study 36003294 — intervention group
Group type: COMPARATOR
Intervention: Control group - only undergoes blood pressure measurements before and after the intervention period.
Number of subjects: 400
Study 32651051 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mA
Number of subjects: 0
Study 32651051 — intervention group
Group type: EXPERIMENTAL
Intervention: 700 mA
Number of subjects: 0
Study 32651051 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mA
Number of subjects: 0
Study 34946280 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentapen R syringe
Number of subjects: 178
Study 34946280 — intervention group
Group type: COMPARATOR
Intervention: Conventional syringe
Number of subjects: 178
Study 33028550 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (single‐pulse TMS to primary motor cortex (M1) above resting motor threshold)
Number of subjects: 22
Study 33028550 — intervention group
Group type: COMPARATOR
Intervention: Inactive treatment (single‐pulse TMS to M1 below resting motor threshold)
Number of subjects: 22
Study 33028550 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 22
Study 36006521 — intervention group
Group type: EXPERIMENTAL
Intervention: Safe Cholecystectomy modules
Number of subjects: 41
Study 36006521 — intervention group
Group type: COMPARATOR
Intervention: Usually scheduled CME activities (control group)
Number of subjects: 41
Study 32242288 — intervention group
Group type: EXPERIMENTAL
Intervention: Dating Matters comprehensive TDV prevention model
Number of subjects: 3301
Study 32242288 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care TDV prevention program
Number of subjects: 3301
Study 32779534 — intervention group
Group type: EXPERIMENTAL
Intervention: Body-weight resistance exercise (BWR)
Number of subjects: 23
Study 32779534 — intervention group
Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 23
Study 32761909 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical phenytoin (10% phenytoin USP)
Number of subjects: 20
Study 32761909 — intervention group
Group type: COMPARATOR
Intervention: Control (carrier alone)
Number of subjects: 20
Study 36224325 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (20 mg twice a day) in group A (S+)
Number of subjects: 158
Study 36224325 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (20 mg twice a day) in group C (S-)
Number of subjects: 158
Study 36224325 — intervention group
Group type: COMPARATOR
Intervention: Placebo in group B (S+)
Number of subjects: 158
Study 36224325 — intervention group
Group type: COMPARATOR
Intervention: Placebo in group D (S-)
Number of subjects: 158
Study 35816305 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin I assay
Number of subjects: 1115
Study 35816305 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 myocardial infarction due to hypoxemia
Number of subjects: 1115
Study 35816305 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 myocardial infarction due to anemia
Number of subjects: 1115
Study 35816305 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 myocardial infarction due to tachyarrhythmia
Number of subjects: 1115
Study 35816305 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 myocardial infarction due to coronary mechanisms
Number of subjects: 1115
Study 35816305 — intervention group
Group type: COMPARATOR
Intervention: Type 1 myocardial infarction
Number of subjects: 1115
Study 34387432 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous costal cartilage‐based open rhinoplasty
Number of subjects: 30
Study 34387432 — intervention group
Group type: EXPERIMENTAL
Intervention: Revision operation
Number of subjects: 30
Study 34387432 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial surgery
Number of subjects: 30
Study 34387432 — intervention group
Group type: COMPARATOR
Intervention: Preoperative measurements
Number of subjects: 30
Study 32770957 — intervention group
Group type: EXPERIMENTAL
Intervention: End-stage renal disease patients receiving CABG
Number of subjects: 48
Study 35751944 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Training for counselors
Number of subjects: 476
Study 35751944 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized Feedback Report (PFR)
Number of subjects: 476
Study 35751944 — intervention group
Group type: COMPARATOR
Intervention: Basic Training for counselors
Number of subjects: 476
Study 35751944 — intervention group
Group type: COMPARATOR
Intervention: No Feedback
Number of subjects: 476
Study 33421315 — intervention group
Group type: EXPERIMENTAL
Intervention: Family empowerment program (8 weeks of group training sessions)
Number of subjects: 82
Study 33421315 — intervention group
Group type: COMPARATOR
Intervention: Usual care education (control group)
Number of subjects: 82
Study 34461803 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary peptidomic profiling (UPP) communicated early during follow-up
Number of subjects: 1148
Study 34461803 — intervention group
Group type: COMPARATOR
Intervention: Home blood pressure telemonitoring (HTM) alone
Number of subjects: 1148
Study 34167763 — intervention group
Group type: EXPERIMENTAL
Intervention: Peek Community Eye Health (Peek CEH) system
Number of subjects: 68348
Study 34167763 — intervention group
Group type: COMPARATOR
Intervention: Standard care via periodic health centre‐based outreach clinics
Number of subjects: 68348
Study 32572864 — intervention group
Group type: EXPERIMENTAL
Intervention: PRECISE-DAPT score
Number of subjects: 15968
Study 32572864 — intervention group
Group type: EXPERIMENTAL
Intervention: CRUSADE score
Number of subjects: 15968
Study 32572864 — intervention group
Group type: EXPERIMENTAL
Intervention: ACUITY score
Number of subjects: 15968
Study 35630063 — intervention group
Group type: EXPERIMENTAL
Intervention: Echinacea angustifolia and purpurea supplementation plus vaginal hyaluronic acid for 3 months
Number of subjects: 153
Study 35630063 — intervention group
Group type: COMPARATOR
Intervention: Echinacea angustifolia and purpurea supplementation alone for 3 months
Number of subjects: 153
Study 35630063 — intervention group
Group type: COMPARATOR
Intervention: Vaginal hyaluronic acid alone for 3 months
Number of subjects: 153
Study 33814366 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-medical students
Number of subjects: 465
Study 33814366 — intervention group
Group type: COMPARATOR
Intervention: Medical students
Number of subjects: 465
Study 35648286 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin
Number of subjects: 100000
Study 35648286 — intervention group
Group type: EXPERIMENTAL
Intervention: Second dose of immunoglobulin
Number of subjects: 100000
Study 35648286 — intervention group
Group type: COMPARATOR
Intervention: Eculizumab (monoclonal antibody against C5)
Number of subjects: 100000
Study 35648286 — intervention group
Group type: COMPARATOR
Intervention: ANX005 (humanized recombinant antibody against C1q)
Number of subjects: 100000
Study 34158000 — intervention group
Group type: EXPERIMENTAL
Intervention: Group exercise intervention (12-week, moderate to vigorous aerobic exercise)
Number of subjects: 38
Study 34304738 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital- and community-based intervention adapted from the Critical Time Intervention, including a six-month period of support in the community after hospital discharge.
Number of subjects: 0
Study 32649617 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic implantation of a biological intraperitoneal mesh using Strattice (mesh group)
Number of subjects: 48
Study 32649617 — intervention group
Group type: COMPARATOR
Intervention: Standard abdominal closure using a single, continuous running suture (no-mesh group)
Number of subjects: 48
Study 35023547 — intervention group
Group type: EXPERIMENTAL
Intervention: Finerenone
Number of subjects: 13026
Study 35023547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13026
Study 33503656 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedside washing of allogeneic erythrocyte units
Number of subjects: 75
Study 34045378 — intervention group
Group type: EXPERIMENTAL
Intervention: Start antiplatelet therapy
Number of subjects: 537
Study 34045378 — intervention group
Group type: COMPARATOR
Intervention: Avoid antiplatelet therapy
Number of subjects: 537
Study 33716269 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA)
Number of subjects: 485
Study 33716269 — intervention group
Group type: COMPARATOR
Intervention: Sedentary behavior (SB)
Number of subjects: 485
Study 33716269 — intervention group
Group type: COMPARATOR
Intervention: Light-intensity physical activity (LPA)
Number of subjects: 485
Study 32996352 — intervention group
Group type: EXPERIMENTAL
Intervention: Schema-enhanced parent behavior therapy (SPBT)
Number of subjects: 54
Study 32996352 — intervention group
Group type: COMPARATOR
Intervention: Parent behavioral training (control group)
Number of subjects: 54
Study 36433863 — intervention group
Group type: EXPERIMENTAL
Intervention: T-PRF
Number of subjects: 118
Study 36433863 — intervention group
Group type: COMPARATOR
Intervention: SCTG
Number of subjects: 118
Study 34214098 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 290
Study 34214098 — intervention group
Group type: COMPARATOR
Intervention: Opioid
Number of subjects: 290
Study 36000769 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma Collaborative Care (TCC) program
Number of subjects: 722
Study 36000769 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 722
Study 33477587 — intervention group
Group type: EXPERIMENTAL
Intervention: FB group (nasal inspiratory restriction device with respiratory muscle training)
Number of subjects: 18
Study 33477587 — intervention group
Group type: COMPARATOR
Intervention: Control group (without respiratory muscle training)
Number of subjects: 18
Study 32559123 — intervention group
Group type: EXPERIMENTAL
Intervention: Science textbook chapter with added prosocial utility value
Number of subjects: 0
Study 32559123 — intervention group
Group type: COMPARATOR
Intervention: Control conditions (two unspecified control conditions)
Number of subjects: 0
Study 32844674 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Scribe Services (VSS)
Number of subjects: 50
Study 32844674 — intervention group
Group type: COMPARATOR
Intervention: Traditional postencounter dictation (TD)
Number of subjects: 50
Study 35606227 — intervention group
Group type: EXPERIMENTAL
Intervention: Atkins diet (55% fat, 25% protein, 20% carbohydrates)
Number of subjects: 24
Study 33447966 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT)
Number of subjects: 60
Study 33447966 — intervention group
Group type: COMPARATOR
Intervention: C-reactive protein (CRP)
Number of subjects: 60
Study 35120541 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice change intervention (multi-strategy including educational meetings and educational materials)
Number of subjects: 0
Study 35120541 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice change intervention
Number of subjects: 0
Study 35120541 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 33369329 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular training of core muscle strength guided by ERAS concept
Number of subjects: 94
Study 33369329 — intervention group
Group type: COMPARATOR
Intervention: Traditional training method
Number of subjects: 94
Study 34928302 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA vaccine (BNT162b2 or mRNA‐1273)
Number of subjects: 201
Study 34928302 — intervention group
Group type: EXPERIMENTAL
Intervention: Vector vaccine (Ad26COVS1)
Number of subjects: 201
Study 34928302 — intervention group
Group type: COMPARATOR
Intervention: mRNA vaccine
Number of subjects: 201
Study 34928302 — intervention group
Group type: COMPARATOR
Intervention: Both mRNA and vector vaccines
Number of subjects: 201
Study 34928302 — intervention group
Group type: COMPARATOR
Intervention: Vector vaccine
Number of subjects: 201
Study 33202263 — intervention group
Group type: EXPERIMENTAL
Intervention: Active ABM training
Number of subjects: 40
Study 33202263 — intervention group
Group type: COMPARATOR
Intervention: Sham ABM training
Number of subjects: 40
Study 34465677 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurodynamics Nerve Flossing Technique (NFT) combined with conventional therapy program
Number of subjects: 30
Study 34465677 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy program
Number of subjects: 30
Study 33210773 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial intervention by primary care nurses including motivational interview and individualized prescription of physical activity (150 min/week)
Number of subjects: 263
Study 33210773 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial intervention by primary care nurses
Number of subjects: 263
Study 33210773 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 263
Study 32613370 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective surveillance and early intervention model of care (PSM)
Number of subjects: 219
Study 32613370 — intervention group
Group type: EXPERIMENTAL
Intervention: Education to health professionals and patients
Number of subjects: 219
Study 32613370 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to nonoptional study appointments
Number of subjects: 219
Study 32613370 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained implementation of PSM
Number of subjects: 219
Study 35343881 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g Egg Protein Hydrolysate (EPH)
Number of subjects: 45
Study 35343881 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g Egg Protein Hydrolysate (EPH)
Number of subjects: 45
Study 35343881 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g and 1 g Egg Protein Hydrolysate (EPH)
Number of subjects: 45
Study 33184931 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrasentan 0.75 mg for 6 weeks
Number of subjects: 4775
Study 36476310 — intervention group
Group type: EXPERIMENTAL
Intervention: ACME (Antrodia Cinnamomea mycelia extract) 250 mg daily for 12 weeks
Number of subjects: 44
Study 36476310 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsule daily for 12 weeks
Number of subjects: 44
Study 34126249 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab or Bevacizumab treatment for neovascular AMD
Number of subjects: 406
Study 36243220 — intervention group
Group type: COMPARATOR
Intervention: Resistance training in normoxia (RTN; n = 17)
Number of subjects: 50
Study 36243220 — intervention group
Group type: COMPARATOR
Intervention: Resistance training in hypoxia (RTH; n = 13)
Number of subjects: 50
Study 36243220 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON; n = 20)
Number of subjects: 50
Study 34078180 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive stereotype
Number of subjects: 50
Study 34078180 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative stereotype
Number of subjects: 50
Study 34078180 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 50
Study 32323609 — intervention group
Group type: EXPERIMENTAL
Intervention: KP-100 (recombinant human hepatocyte growth factor) administered intrathecally
Number of subjects: 43
Study 32323609 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 32323609 — intervention group
Group type: EXPERIMENTAL
Intervention: KP-100
Number of subjects: 43
Study 35959712 — intervention group
Group type: EXPERIMENTAL
Intervention: Large particle (LP) size graft
Number of subjects: 22
Study 35959712 — intervention group
Group type: COMPARATOR
Intervention: Small particle (SP) size graft
Number of subjects: 22
Study 35959712 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 22
Study 33332919 — intervention group
Group type: EXPERIMENTAL
Intervention: Phrenic nerve block (PNB) with 10 mL of 0.375% ropivacaine
Number of subjects: 85
Study 33332919 — intervention group
Group type: COMPARATOR
Intervention: Control group with 0.9% saline
Number of subjects: 85